Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidant Galileo

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement is filed with FDA for a next-generation version of the intravascular radiation system for in-stent restenosis that incorporates an automated "stepping function" to automatically reposition the radiation source and facilitate treatment of long lesions. Called the GalileoIII, the device uses a third generation centering catheter, Guidant explains. The current version of the system, approved Nov. 2, permits treatment of long lesions via manual tandem repositioning (1"The Gray Sheet" Nov. 12, 2001, p. 3). Pending approval, customers with existing systems will be upgraded at no additional cost, the firm says...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel